Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Underestimation of Cutaneous Squamous Cell Carcinoma Incidence, Even in Cancer Registries

Underestimation of Cutaneous Squamous Cell Carcinoma Incidence, Even in Cancer Registries Opinion Editorial options is under way. Even procedures as seemingly or more medications are labeled as allergies, limiting future straightforward as estimation of BSA involvement in EN therapeutic options. Combined in vivo and ex vivo testing (defined in SCORTEN as the sum of detached and detachable via patch testing and interferon-γ release assay, respec- epidermis ) are subject to interobserver variability depending tively, have been used safely in a pilot study to assign drug on the specific formula used and the extent of cutaneous causality with moderate sensitivity and high specificity. involvement. Similarly, while in-hospital mortality is an Further investigation is needed to devise a personalized objective, defined outcomes and proxy outcomes like time- approach to drug hypersensitivity testing and safe medica- to-reepithelization are often poorly defined or of uncertain tion prescribing among survivors of EN. significance as surrogate markers of treatment response. In conclusion, future clinical and translational research in Consistent terminology, rigorous disease metrics, and EN should focus on improving and standardizing prevention, meaningful, evidence-based outcomes are essential for diagnosis, and treatment options for patients. Multi- successful conduct of EN-related research around the world. institutional, international collaborations with standardized, Understanding and addressing the long-term physical and evidence-based http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Underestimation of Cutaneous Squamous Cell Carcinoma Incidence, Even in Cancer Registries

JAMA Dermatology , Volume 156 (12) – Dec 28, 2020

Loading next page...
 
/lp/american-medical-association/underestimation-of-cutaneous-squamous-cell-carcinoma-incidence-even-in-A9QqxDTFT9
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2020.3678
Publisher site
See Article on Publisher Site

Abstract

Opinion Editorial options is under way. Even procedures as seemingly or more medications are labeled as allergies, limiting future straightforward as estimation of BSA involvement in EN therapeutic options. Combined in vivo and ex vivo testing (defined in SCORTEN as the sum of detached and detachable via patch testing and interferon-γ release assay, respec- epidermis ) are subject to interobserver variability depending tively, have been used safely in a pilot study to assign drug on the specific formula used and the extent of cutaneous causality with moderate sensitivity and high specificity. involvement. Similarly, while in-hospital mortality is an Further investigation is needed to devise a personalized objective, defined outcomes and proxy outcomes like time- approach to drug hypersensitivity testing and safe medica- to-reepithelization are often poorly defined or of uncertain tion prescribing among survivors of EN. significance as surrogate markers of treatment response. In conclusion, future clinical and translational research in Consistent terminology, rigorous disease metrics, and EN should focus on improving and standardizing prevention, meaningful, evidence-based outcomes are essential for diagnosis, and treatment options for patients. Multi- successful conduct of EN-related research around the world. institutional, international collaborations with standardized, Understanding and addressing the long-term physical and evidence-based

Journal

JAMA DermatologyAmerican Medical Association

Published: Dec 28, 2020

References